Marksans Pharma gains after USFDA clears Goa facility

Marksans Pharma experienced an increase of 1.94%, reaching Rs 186.30, following the announcement that it received zero observations during a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration (USFDA) at its facility in Goa plant.

In an exchange filing, the company indicated that the inspection took place at its second manufacturing site, located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India, from 3 November 2025 to 7 November 2025. The inspection concluded without any Form 483 observations. Mark Saldanha, the managing director, stated that the successful outcome of the cGMP inspection by the US FDA reflects our continuous dedication to product quality and adherence to regulatory standards.

Also Read: Boehringer Ingelheim Licenses Autoimmune Drug from Kyowa Kirin

Marksans Pharma is primarily involved in the research manufacturing, marketing sales, and pharmaceutical formulations.

The company’s consolidated profit fell by 34.3% to Rs 58.31 crore, despite a 4.97% increase in revenue operations, which reached Rs 619.98 crore in Q1 FY26 compared to Q1 FY25.

Marksans Pharma is an Indian pharmaceutical firm based in Mumbai city, engaged in the research manufacturing and marketing distribution of finished dosage pharmaceutical formulations for international markets.

The company’s product range includes both over-the-counter (OTC) and prescription drugs, addressing a variety of therapeutic areas such as pain management, cough cold, digestive health, cardiovascular system, central nervous system (CNS), anti-diabetics antibiotics. Marksans Pharma operates on a global scale, with a presence in over 50 countries. Its manufacturing facilities meet the standards set by major international regulatory bodies, including the UK MHRA and Australian TGA.